stockrow
Saturday 7 November 2026
Export JUNS’s income statement to Excel — free account
Jupiter Neurosciences, Inc.
JUNS Healthcare Biotechnology
Jupiter Neurosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21,800.00, down 90.7% from fiscal 2022.
- EPS
- +22.5%
- Free cash flow
- −177.1%
Quarter to June 2026, against a year earlier
2.27
0.14
+6.57%
Follow JUNS
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 0 | — | — | 0 | — | (54.6%) | 11 | 4 | — | +1,280.2% | |
| Gross margin, % | — | — | — | — | — | — | 100.00 | — | — | 80.73 | — | (19.3) pt | ||||||
| EBT | — | — | — | — | — | — | (5) | (5) | (2) | (9) | (9) | +20.4% | ||||||
| EBT margin, % | — | — | — | — | — | — | (2,124.99) | 0.00 | 0.00 | (39,655.50) | 0.00 | (37,530.5) pt | ||||||
| Net income | — | — | — | — | — | — | (5) | (5) | (2) | (9) | (9) | +20.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.69 | 0.00 | 0.00 | 0.05 | 0.00 | (59.1%) | |||||
| Earnings | — | — | — | — | — | — | (14.65) | (13.62) | (6.01) | (18.80) | (19.12) | +8.7% | ||||||
| Cash flow | — | — | — | — | — | — | (3.69) | (1.37) | (10.22) | (11.75) | (13.00) | +47.2% | ||||||
| Capex | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | (3.69) | (1.37) | (10.22) | (11.75) | (13.00) | +47.2% | ||||||
| Book value | — | — | — | — | — | — | (21.11) | (16.52) | 10.90 | (3.98) | (0.66) | (42.7%) | ||||||
| Shares, m | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | +10.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | — | — | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 0.00 | — | — | 0.00 | 0.00 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | 0.00 | — | — | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | — | — | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | (452.44) | — | — | (5.83) | 0.02 | (229.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (1) | 0 | (4) | (5) | (7) | +63.1% | |||||
| Capex | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Free cash flow | — | — | — | — | — | — | (1) | 0 | (4) | (5) | (7) | +63.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | (7) | (6) | 3 | (3) | (1) | (29.0%) | |||||
| Net debt | — | — | — | — | — | — | 0 | 0 | (4) | (4) | (2) | +288.9% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (7) | (6) | 4 | (2) | 0 | (36.5%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (2,488.27) | (76.83) | (146.94) | (239.36) | (146.9) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | (480.02) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 73.91 | 299.45 | (738.85) | (1,888.80) | (738.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 4 | 4 | 10 | — | +58.1% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Jupiter Neurosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ERNA Ernexa Therapeutics Inc. | $3.0M | — (loss-making) | — (loss-making) | −94.12% (below 0%: shrinking) | n/m | −64.10% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MBIO Mustang Bio, Inc. | $3.0M | — (loss-making) | — | — | n/m | +27.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CMND Clearmind Medicine Inc. | $3.0M | — (loss-making) | — | — | n/m | −77.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KALA KALA BIO, Inc. | $3.0M | — (loss-making) | — (loss-making) | −86.31% (below 0%: shrinking) | n/m | +80.19% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BCAB BioAtla, Inc. | $2.9M | — (loss-making) | — (loss-making) | +4,233.33% (above 0%: growing) | n/m | +97.03% (above 0%: growing) | 100.00% | 3.49% | Compare |
| JUNS Jupiter Neurosciences, Inc. | $2.8M | — (loss-making) | — | — | n/m | −177.06% (below 0%: shrinking) | 87.19% | (11,334.30%) | |
| AFMDQ Affimed N.V. | $2.8M | — (loss-making) | — (loss-making) | −92.02% (below 0%: shrinking) | n/m | +46.95% (above 0%: growing) | 100.00% | (9,216.90%) | Compare |
| DCOY Decoy Therapeutics Inc | $2.7M | — (loss-making) | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| NRSN NeuroSense Therapeutics Ltd. | $2.6M | — (loss-making) | — | — | n/m | −23,458.82% (below 0%: shrinking) | — | 0.00% | Compare |
| Median of peers | $2.9M | — | — | −86.31% | — | −18.16% | 100.00% | 0.00% |
Pay and ownership Proxy statement filed 22 June 2026
Ownership
Directors and executive officers, together
38.60%
Christer Rosén
25.80%
Marshall Hayward, Ph.D.
8.10%
Claes Wahlestedt, M.D., Ph.D.
6.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement